This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Academic Highlights

Optimizing Pharmacotherapy to Maximize Outcome in Schizophrenia

John M. Kane, M.D.; Anissa Abi-Dargham, MD; Stephen R Marder, MD; Peter J. Weiden, M.D.; Rajiv Tandon, MD; and Henry A. Nasrallah, MD

Published: January 15, 2005

Article Abstract

Click to enlarge page

Although abundant evidence shows that dysfunction in multiple neurotransmitter systems (including the serotonergic and the glutamatergic systems) contributes to the pathogenesis of schizophrenia, alterations in dopaminergrc systems are the best-documented neurochemical dysfunctions associated with this illness, according to Anissa Abi-Dargham, M.D. The modern dopamine hypothesis of schizophrenia proposes that positive symptoms of psychosis in patients with schizophrenia arise from a condition of up-regulated dopaminerglc neuronal activity in subcortical pathways, whereas negative symptoms and cognitive impairment result from a dopamine deficit in the cortical dopamine (DA) pathways. Traditional support for this hypothesis derives from the fact that typical antipsychotic agents, whose main property is the antagonism of D2 dopamine receptors, suppress positive symptoms but do not significantly improve and may even worsen negative symptoms.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 66

Quick Links: